Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 4gamma-Globulins 3Ciprofloxacin 3Immunoglobulins, Intravenous 2Dexamethasone 2Amoxicillin-Potassium Clavulanate Combination 2daratumumab 1Thalidomide 1MAGEA3 protein, human 1Lenalidomide 1Immunoglobulins 1Clavulanic Acid 1Calcium Dobesilate 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasms, Plasma Cell × MAGEA3 protein, human × Clear all
NCT00090493 2013-06-24

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

University of Arkansas

Phase 2/3 Completed
4 enrolled 6 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡